Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Disc Medicine (IRON – Research Report). The associated price target remains the same with $85.00.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight Disc Medicine’s promising financial and clinical position. The company has reported a strong cash position, ending the fiscal year with nearly $490 million in cash and marketable securities, and securing additional funds through a public offering. This financial stability is expected to support operations through 2028, providing a solid foundation for the company’s ongoing and future projects.
Moreover, Disc Medicine’s clinical pipeline, particularly the progress with bitoperin, contributes to the positive outlook. The company plans to submit a New Drug Application for bitoperin under the accelerated approval pathway, supported by promising data from previous studies. Additionally, the alignment with the FDA on the design of the confirmatory APOLLO study further strengthens the potential for successful outcomes. These factors, combined with the observed efficacy of bitoperin in reducing PPIX levels, underpin the Buy rating as they indicate a high probability of success in upcoming clinical trials.